Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03932201 · ClinicalTrials.gov registry record
Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A
A clinical trial of Hemophilia A, sponsored by Bayer.
- Active
- Registry status
- 371
- Enrollment target
- 20
- Study locations
NCT03932201: Active study of Hemophilia A, sponsored by Bayer.
NCT03932201 is a study of Hemophilia A that is active but no longer recruiting, run by Bayer. The registered enrollment target is 371 participants, above the 83-participant average among 42 other Hemophilia A trials with a reported enrollment target (347% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03932201, a study of Hemophilia A, is active but no longer recruiting, sponsored by Bayer.
- ACTIVE NOT RECRUITING
- Registry status
- 371 participants
- Enrollment target
- 20
- Study locations
Study Summary
The aim of the HEM-POWR study is to understand better how Damoctocog alfa pegol (Jivi) is used to treat people with Hemophilia A in day-to-day life, how well the treatment is tolerated and how satisfied patients and physicians are with the treatment.
Conditions Studied
Interventions
- DRUG Damoctocog alfa pegol (Jivi, Bay94-9027)
Study Locations (20)
Other
- Many locations - Multiple Locations
- Many locations - Multiple Locations
- Many locations - Multiple Locations
- Many locations - Multiple Locations
- Many locations - Multiple Locations
- Many locations - Multiple Locations
- Many locations - Multiple Locations
- Many locations - Multiple Locations
- Many locations - Multiple Locations
- Many locations - Multiple Locations
California
- University California Davis - Davis
- Orthopaedic Hospital DBA Orthopaedic Institute for Children - Los Angeles
- The Center for Comprehensive Care and Diagnosis of Inherited Blood Disorders - Orange
Alabama
- South Alabama Medical Science Foundation - Mobile
Arizona
- Banner MD Anderson Cancer Center - Phoenix
Colorado
- University of Colorado Hemophilia and Thrombosis Center - Aurora
District of Columbia
- Georgetown University - Washington D.C.
Louisiana
- Tulane University - New Orleans
Minnesota
- Regents of University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 371 participants |
| Start Date | 2019-10-21 |
| Est. Completion | 2027-03-31 |
What the registry record for NCT03932201 still lists
NCT03932201 is an observational study that tracks outcomes without assigning an intervention. The registered 371 participants enrollment target is mid-sized for trials with a published cap, above the 83-participant average among 42 other Hemophilia A trials with a reported enrollment target (347% higher).
The record links to 1 condition, with Hemophilia A appearing as the primary indexed condition, and to 1 intervention - of which Damoctocog alfa pegol (Jivi, Bay94-9027) is the first listed.
NCT03932201 names 20 study sites across 9 states, led by Other, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT03932201 about?
NCT03932201 is a clinical study titled "Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A". The aim of the HEM-POWR study is to understand better how Damoctocog alfa pegol (Jivi) is used to treat people with Hemophilia A in day-to-day life, how well the treatment is tolerated and how satisfied patients and physicians are with the treatment.
What is the current status of trial NCT03932201?
This trial is currently active not recruiting. The enrollment target is 371 participants. The study started on 2019-10-21. Estimated completion is 2027-03-31.
What conditions does trial NCT03932201 study?
This clinical trial studies the following conditions: Hemophilia A.
What interventions are being tested in trial NCT03932201?
The interventions under investigation include: Damoctocog alfa pegol (Jivi, Bay94-9027) (DRUG).
Who is sponsoring clinical trial NCT03932201?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03932201 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemophilia A
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03932201's enrollment target sits among peer trials
371 2nd of 42 the highest of 42 other Hemophilia A trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hemophilia A trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
RECRUITING · Phase 3
-
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
RECRUITING · Phase 3
-
A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
RECRUITING · Phase 1
-
Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery
RECRUITING · Phase 4
-
Hemophilia A Research Program
RECRUITING
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05743673 · 371 participants
SHAPE Test for Preoperative Risk Stratification
- NCT05761847 · 371 participants · NA
Pediatric Medication Therapy Management Trial
- NCT04801589 · 372 participants · Phase 3
Goal-Directed Sedation in Mechanically Ventilated Infants and Children
- NCT04879329 · 372 participants · Phase 2
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI